Immunome, Inc. (IMNM)

Mixed fundamentals: the company has a sizable cash runway and meaningful regulatory progress on its lead program, but it remains pre-revenue on a trailing basis with heavy cash burn and negative free-cash-flow yield. With high volatility and a discounted-cash-flow estimate far below the current share price, the risk/reward is driven primarily by clinical and regulatory execution rather than current operating profitability.

Dominant catalyst is the varegacestat NDA under FDA review (announced; PDUFA April 2027) — real but digested and outside the 30-day horizon; the news delta is determinate but flat-to-slightly-positive (+0.012 baseline → +0.067 scoring, both near zero) with no in-window market-rewarded bullish event beyond a routine $40 price-target reiteration; the red-flag screen fired no severe or moderate flags, and the setup is weak/forming without a near-term driver.

Price 24.67 sits below SMA20 (27.47), SMA50 (25.27), EMA9 (26.26), EMA21 (26.59), WMA/DEMA/TEMA and daily VWAP (25.00) after three consecutive down sessions from 27.25; ADX14 50.77 confirms a strong trend that is pointing DOWN given price below all short/intermediate averages, RSI14 39.27 and Williams %R -98.63 are oversold but without a bullish turn, and MACD line is barely above zero (0.08) with a negative histogram (-0.55), i.e. momentum is rolling over, not re-engaging. The only bullish context is the hold above the rising SMA200 (22.48). Net chart quality is bounce-only/neutral-bearish (raw ~2), and the score is additionally capped at 2 by the stale-feed gate: no run-date source exists in this partial run, so no current chart can be certified.